Pinned Tweet
After 14 wonderful years at @BrighamWomens, @MassGenBrigham, @DanaFarber, and @VABostonHC, I am happy to announce that I will be the Director of @MountSinaiHeart at @MountSinaiNYC and the Dr. Valentin Fuster Professor of CV Medicine at @IcahnMountSinai. mountsinai.org/about/newsroo…
Dr. Deepak L. Bhatt retweeted
From breakthrough research in acute coronary syndromes to innovations in coronary artery disease and cardiovascular-kidney-metabolic health, hear from @DLBHATTMD at #ScientificSessions26.
@AHAScience @IcahnMountSinai
#CardioX #Cardiology
✅Lp(a) at the #AHA26 - no 💊 pharma yet on the HORIZON. So should we still screen it ? Does Knowing Lp(a) Change What We Do? See the debate in #EJPC ⤵️ academic.oup.com/eurjpc/arti…
@escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic @GalTsaban @DLBHATTMD
Kicking off #AHA2026 with these amazing colleagues. Awaiting full results of HORIZON and ZEUS.@BudoffMd @DLBHATTMD Leslie Cho.
What we know from Lp(a)HORIZON and what remains unknown
The Lp(a)HORIZON trial is a landmark study whose negative primary endpoint result must be interpreted with the precision the underlying science demands. The causal role of Lp(a), the ability to lower Lp(a) pharmacologically, and the clinical benefit of that reduction are distinct propositions, and only the third is directly tested by this trial.
@DLBHATTMD @DrMarthaGulati @hvanspall @CMichaelGibson
sciencedirect.com/science/ar…
Dr. Deepak L. Bhatt retweeted
Some thoughts about HORIZON as we await the formal data at #AHA26. #cardiology #cardiovascular #prevention #cardiotwitter #cardioX
Lp(a)HORIZON was negative. But what exactly did it disprove?
Not that Lp(a) is causal.
Not that we can lower it.
It challenged whether pharmacologic lowering reduces events.
The full data with component outcomes, precision, subgroup analyses, and timing will determine what comes next.
New viewpoint in @PCVDJournal
@AbdelazizMD1 @DLBHATTMD @ElsevierConnect
sciencedirect.com/science/ar…
From breakthrough research in acute coronary syndromes to innovations in coronary artery disease and cardiovascular-kidney-metabolic health, hear from @DLBHATTMD at #ScientificSessions26.
@AHAScience @IcahnMountSinai
#CardioX #Cardiology
Some thoughts about HORIZON as we await the formal data at #AHA26. #cardiology #cardiovascular #prevention #cardiotwitter #cardioX
Lp(a)HORIZON was negative. But what exactly did it disprove?
Not that Lp(a) is causal.
Not that we can lower it.
It challenged whether pharmacologic lowering reduces events.
The full data with component outcomes, precision, subgroup analyses, and timing will determine what comes next.
New viewpoint in @PCVDJournal
@AbdelazizMD1 @DLBHATTMD @ElsevierConnect
sciencedirect.com/science/ar…
Dr. Deepak L. Bhatt retweeted
The 10-year results from the REGROUP trial are out now in @CircAHA! #cardiovascular #surgery #cardiotwitter #cardioX #cardiology @VABostonHC @DeptVetAffairs
Delighted to share our 10-year REGROUP RCT results in @CircAHA: no difference in MACE, death, MI or repeat revascularization between endoscopic and open vein harvesting for CABG. Thanks to @MarcoZenatiMD for his mentorship, Dr. Gaziano’s valuable support, and all collaborators.
Dr. Deepak L. Bhatt retweeted
⏱️ Faster action could change the course of recurrent AMI. Explore emerging prehospital treatment strategies and practical approaches to reducing ischemic time and optimizing care pathways. 🫀 @jennifer_rymer, @DLBhattMD & @ShaunGoodman
🚑 Explore more: mdsc.pe/4zgu7au
Very interesting analysis by @nihardesai927 - Real-world comparative effectiveness of evolocumab versus ezetimibe in… sciencedirect.com/science/ar…
An expert diagnostic and therapeutic pathway for obesity – the ADIPO-CARE Plan. Just published in the Nutrients. We invite you to read it!
mdpi.com/2072-6643/18/21/366…
@DLBHATTMD @ProfKausikRay @DrMichaelShapir @escardio @LiverpoolCCS @society_eas @nationallipid
The 10-year results from the REGROUP trial are out now in @CircAHA! #cardiovascular #surgery #cardiotwitter #cardioX #cardiology @VABostonHC @DeptVetAffairs
Delighted to share our 10-year REGROUP RCT results in @CircAHA: no difference in MACE, death, MI or repeat revascularization between endoscopic and open vein harvesting for CABG. Thanks to @MarcoZenatiMD for his mentorship, Dr. Gaziano’s valuable support, and all collaborators.
⏱️ Faster action could change the course of recurrent AMI. Explore emerging prehospital treatment strategies and practical approaches to reducing ischemic time and optimizing care pathways. 🫀 @jennifer_rymer, @DLBhattMD & @ShaunGoodman
🚑 Explore more: mdsc.pe/4zgu7au
⏱️ Faster action could change the course of recurrent AMI. Explore emerging prehospital treatment strategies and practical approaches to reducing ischemic time and optimizing care pathways. 🫀 @jennifer_rymer, @DLBhattMD & @ShaunGoodman
🚑 Explore more: mdsc.pe/4zgu7au
Dr. Deepak L. Bhatt retweeted
In a new episode of #ACCEL Lite, Drs. @ditchhaporia and @DLBHATTMD discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug targeting inflammation in CKD with high cardiovascular risk.
Listen to the episode: bit.ly/4sobqzy
Dr. Deepak L. Bhatt retweeted
Meet the visionary leaders behind CMHC 2026! 👏 A huge thank you to Dr. Anne L. Peters, Dr. Christie M. Ballantyne, Dr. Robert H. Eckel, Dr. Keith C. Ferdinand, and renowned faculty Dr. Deepak L. Bhatt for their expertise and dedication in shaping an exceptional conference experience. #CMHC2026 #CMHCBoston #21stAnnualCMHC
@CBallantyneMD
@DLBHATTMD
Meet the visionary leaders behind CMHC 2026! 👏 A huge thank you to Dr. Anne L. Peters, Dr. Christie M. Ballantyne, Dr. Robert H. Eckel, Dr. Keith C. Ferdinand, and renowned faculty Dr. Deepak L. Bhatt for their expertise and dedication in shaping an exceptional conference experience. #CMHC2026 #CMHCBoston #21stAnnualCMHC
@CBallantyneMD
@DLBHATTMD



























